ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation

Authors

  • Riyaz A Kaba 1. Ashford & St Peter’s Hospitals NHS Foundation Trust, Chertsey, UK 2. Epsom General Hospital NHS Trust, Epsom, UK 3. George’s Hospital NHS Trust, London, UK
  • Omar Ahmed Ashford & St Peter’s Hospitals NHS Foundation Trust, Chertsey, UK
  • Douglas Cannie Epsom General Hospital NHS Trust, Epsom, UK

Abstract

Recent trials have presented compelling evidence for the safety and efficacy of the new oral anticoagulants (NOACs) versus warfarin for stroke prevention in patients with atrial fibrillation (AF). The ENGAGE AF-TIMI 48 trial, the biggest of these trials, aims to evaluate the use of the direct factor Xa inhibitor, edoxaban. 

Downloads

Published

2017-06-01

Issue

Vol. 2013 No. 4 (2013)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.